Related Experiment Video

Updated: Sep 22, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas

Nikolaus von Knebel Doeberitz1, Daniel Paech1,2, Dominik Sturm3,4,5

  • 1Division of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

International Journal of Cancer
|May 23, 2022
PubMed

Insights

Glioma cells resist apoptosis-based treatments by disabling p53/p16. Targeting epigenetic repressors reactivates glial maturation genes, halting glioma replication independently of p53/p16.

Area of Science:

  • Neuro-oncology
  • Epigenetics
  • Cancer Biology

Background:

  • Glial-lineage malignancies (gliomas) often mutate apoptosis regulators (p53, p16/CDKN2A), limiting cytotoxic therapy efficacy.
  • Glioma cells retain lineage-specifying transcription factors but fail to activate late-lineage maturation genes due to epigenetic dysregulation.

Purpose of the Study:

  • To investigate the role of epigenetic mechanisms in glioma self-replication.
  • To identify non-cytotoxic therapeutic targets for gliomas by understanding lineage-specific transcription factor circuits.

Main Methods:

  • Analysis of p53/p16 status in gliomas.
  • Investigation of epigenetic machinery and chromatin states in glioma cells.
  • Pharmacological inhibition of epigenetic repressing enzymes.

Main Results:

  • Glioma cells exhibit disrupted epigenetic components and amplified repressing machinery, preventing lineage maturation.
  • Pharmacological inhibition of epigenetic repressors reactivates late-glial genes.
  • This epigenetic targeting terminates glioma self-replication independently of p53/p16 and apoptosis pathways.

Conclusions:

  • Aberrant epigenetic repression of late-lineage programs is causally linked to malignant glioma self-replication.
  • Targeting epigenetic enzymes offers a promising non-cytotoxic therapeutic strategy for gliomas.
  • Lineage-specifying transcription factors are key targets for novel glioma therapies.
Keywords:
cancer epigeneticsepigeneticgliomaglioma therapyneurooncology

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K